Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Salsa Technology Forges Partnership with Brazil’s Fábrica Bets

Salsa Technology  has today officially launched a strategic content partnership with Brazilian sports betting platform provider Fábrica Bets.This collaboration will power Fábrica Bets’ online casino offering, by expanding its reach and delivering an exceptional gaming experience to its extensive user base. Over the years Salsa Gator’s large portfolio of localised titles has grown to become a true leader in the region.  Fábrica Bets, which operates more than 4,000 betting sites, has gained significant recognition for its high-quality sports betting platform.

Communiqué from Bio-Works Technologies’ annual general meeting 2023

Bio-Works Technologies’ annual general meeting was held 26 May 2023. The following resolutions were made at the annual general meeting, among other resolutions.The meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2022. The meeting resolved that no dividend shall be paid for the financial year 2022. The meeting granted the board members and CEO discharge from liability for the financial year 2022. The meeting resolved that the number of board members shall be four and re-elected Peter

Minutes of the Annual General Meeting 2023 in Brain+ A/S

On Friday 26[th] of May at 08:00 CET, Brain+ A/S held its Annual General Meeting. The meeting was held at the company’s home address at Købmagergade 53, 3. 1150 Copenhagen with the following agenda:Agenda 1. Election of Chairman of the meeting 2. The Board of Directors’ report on the company’s activities during the past account year 3. Approval of the Annual Report 2022 4. Resolution as to the appropriation of profits or the covering of losses according to the approved annual accounts 5. Election of members of the Board of Directors 6. Election of auditor 7. Motions or

Atria completes the repurchases of own shares

Atria Plc, Company announcement, 26 May 2023 at 10:30Atria completes the repurchases of own sharesAs communicated on 20 March 2023, the Board of Directors of Atria Plc decided to use the authorisation given by the Annual General Meeting held on 3 May 2022 to repurchase the company’s own A-shares.The repurchases started on 27 March 2023 and ended on 25 May 2023. During this period, Atria repurchased 100,000 A-shares for an average price of EUR 10.8139 per share, corresponding to approximately 0.35% of the total number of the company’s shares, which is 28,267,728.The repurchased

Coloreel reaches milestone with 100 patents, strengthening its robust patent portfolio

Coloreel has obtained its 100th patent, adding to its already substantial portfolio of worldwide patents for its innovative digital thread dyeing technology.Coloreel’s technology allows any embroidery machine to instantly customize thread color during production. Paired with Coloreel, embroidery machines can access millions of precise colors in real time.  The company has in total 14 patent families which are active in 45 key countries. This comprehensive range of patents currently in use covering all essential aspects of Coloreel’s technology and products. The patents cover the current

BioStock: Curasight solidifies position with Curium deal and strong financials

Copenhagen-based biotechnology company Curasight recently released its Q1 2023 report, unveiling a significant stride in its continued journey towards improving cancer diagnosis and treatment. The quarter’s highlight was undoubtedly the company’s partnership agreement with Curium. This move not only reinforced the technological strength of its uTRACE platform but also strategically positioned Curasight to better serve patients on a global scale.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/curasight-solidifies-position-with-curium-deal-and-strong-financials/

Invitation to Sitowise's Capital Markets Day on 7 June 2023

Sitowise Group Plc    Investor News    26 May 2023 Sitowise invites analysts, institutional investors and other capital market representatives to its Capital Markets Day on 7 June 2023. The event will be held in Espoo, Finland at the Accountor Tower (address: Keilaniementie 1). The aim of the Capital Markets Day is to share and discuss Sitowise's new strategy and value creation opportunities, as well as present growth opportunities through concrete examples. Anyone can follow the event via a live webcast at https://sitowise.videosync.fi/cmd-2023 

H&M Foundation donates USD250,000 in response to Cyclone Mocha

In response to the extremely severe Cyclone Mocha that has hit Myanmar and Bangladesh, H&M Foundation is donating USD250,000 to the Red Cross/Red Crescent In the afternoon of 14 May 2023 an extremely severe Cyclone Mocha, the strongest one in the last 10 years, hit the coastal areas along the Bangladesh-Myanmar border, bringing heavy rainfall, strong winds, flooding, and landslides in coastal and low laying areas. Both countries have witnessed significant damage on infrastructures, agriculture, and livelihoods in affected areas. Karl-Johan Persson, H&M Foundation board member,

BioStock: Iconovo initiates structured sales process for ICOpre

Iconovo is currently in negotiations with global pharmaceutical companies regarding the company's latest developed inhaler platform, ICOpre. The company has engaged the global investment bank Stifel to maximize the value and structure the outlicensing process. BioStock contacted Iconovo's CEO Johan Wäborg to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/iconovo-initiates-structured-sales-process/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Life science solutions keeps Ingrid from losing her sight

If it wasn’t for the life science industry and its ability to discover and bring forward new drugs, Getinge employee Göran Carlsson’s mother would’ve been fully blind: “Seeing the proof up so closely, of what our customers can accomplish with the help of our solutions is simply amazing.” Losing sight is something that happened gradually to Ingrid Carlsson. She had been using glasses for her whole life, and about 20 years ago it got worse. “I first got a blood clot in my right eye, followed by the left. Things started to take new shapes as I had difficulties distinguishing

Shape Robotics is appointed exclusive distributor of DOBOT in Romania and Republic of Moldova

On May 25th, 2023, Shape Robotics subsidiary in Romania signed an exclusive distribution agreement with Shenzhen Yuejiang Technology Co., Ltd, a People’s Republic of China, known as the producer of DOBOT Robots. Shape Robotics has been appointed as exclusive distributor of DOBOT equipment in Romania and Republic of Moldova and was granted a non-exclusive licence to sell DOBOT equipment in Bulgaria. Founded in 2015, Dobot Robotics is the creator of the world's first desktop grade collaborative robot and offers 6 main product lines: CR, CRS, MG400, M1 Pro, Nova, and Magician, with more

DanCann Pharma A/S has secured 71 percent of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that they today received underwriting commitments of approximately DKK 5.6 million, regarding subscription options of series TO 2 ("TO 2"), meaning that approximately 71 percent of the issue volume in TO 2 is guaranteed.The number of TO 2s amounts to 21,927,810, whereby each (1) TO 2 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of DKK 0.36 during the period from 16

Cereno Scientific AB announces outcome in the company’s rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Cereno Scientific AB (publ) ("Cereno Scientific" or the "Company") has completed the rights issue of units, consisting of shares of series B and warrants of series TO3, which the board

Frontier markets are facing a credit crunch and heightened risk of debt distress

During the last decade, new sources of financing opened, especially for those lower-income countries catching up with emerging economies, many of which are called frontier markets[1]. The decade after the global financial crisis was characterized by ample liquidity and low interest rates in global financial markets and leading to investors seeking yield in riskier markets. At the same time, China significantly increased its overseas lending, specifically targeting emerging and developing economies. China’s agenda was to ensure access to natural resources needed to spur its fast growth and

DanCann Pharma A/S has successfully completed pre-validation batches and expects final approval from the Danish Medicines Agency by the end of summer

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, is pleased to announce the completion of its pre-validation batches. These batches are paving the way for the Company's forthcoming application to the Danish Medicines Agency for its final inspection of Biotech Pharm1 (“BP1”), seeking approval for the release of its products. This achievement aligns closely with the Company's original expectations, with minor adjustments made along the way.As communicated in December 2022, three

1st Quarter Results and Outline of 2023 Workplan

("Amaroq" or the "Corporation" or the "Company") 1[st] Quarter Financial Results and Outline of 2023 Workplan TORONTO, ONTARIO - [26] May 2023 - Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets covering an area of 7,866.85 km[2] in Southern Greenland, is pleased to present its Q1 2023 Financial Results and outline its current workplan for 2023. Q1 2023 Corporate Highlights: · Debt funding non-binding term sheets for a $66.8 million (US$49.5 million) senior

Acuvi strengthens management team with new CTO

The Acuvi leadership team gets a boost with the joining of Karin Thurberg as CTO. Karin is a long-time telecom industry heavyweight having served in senior management positions in companies like Ericsson and Huawei. She has a background of having led sales roles as well as business development and product development functions in major technology companies.Acuvi is poised to strengthen its position in the sector with the upcoming launch of its high-tech micromotor platform ULTRA. This revolutionary miniature platform delivers nanometer precision combined with the best power ratio in its

Nordic Capital appoints Mohit Agnihotri as new Partner

Significant addition to Nordic Capital Advisors’ leading Technology & Payments team Nordic Capital Advisors has today announced the appointment of Mohit Agnihotri as a Partner.  Mohit has over two decades of investment banking, investing and consulting experience in Financial Technology, Payments and broader Software & Technology sectors.  He will now become a key member of Nordic Capital Advisors’ leading Technology & Payments team and will be based in London.Mohit has extensive transactional experience in the Fintech, Payments and Software sectors globally through his previous

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

26 May 2023  Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy DUO-E is the first global Phase III trial of immunotherapy plusPARP inhibition to demonstrate clinical benefit in this setting Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically

The subscription period in Bioservo’s rights issue begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION.Today, May 26, 2023, the subscription period in Bioservo Technologies AB’s (“Bioservo” or the “Company”) rights issue of approximately MSEK 37 begins, which was resolved by the board of directors of Bioservo on May 15, 2023, based on the authorisation of the

HC Andersen Capital Events 26/5: Meet the management in Tryg, Qlife and GomSpace

HC Andersen Capital is today hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.How does Tryg work with innovation?Get updated on how the insurance company Tryg works with innovation when we host an event about this specific subject.From Tryg we have COO and member of the group management Lars Bonde, who for many years has been responsible for IT and Nordic Innovation - Lars will update us on how Tryg works with new services and products. The event will be held in Danish.Disclaimer: HC Andersen Capital receives

DanCann Pharma A/S in advanced talks with new investor of additional DKK 12 million for topping up the outcome of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby inform the market and its investors that it is currently engaged in advanced discussions with a new investor regarding an additional DKK 12 million to supplement the outcome of TO 2's. The agreement is based on a loan agreement with conversion options and initially has a scope of DKK 12 million, which can potentially increase to a total of DKK 18 million. The agreement will be subject to an approval on an Extra General Meeting.

Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023

Opening remarks   During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H.   Hamlet Pharma has also successfully completed its Horizon 2020 project, receiving the last part of the grant, which means full funding. The European Commission commended Hamlet Pharma for its progress and stated that the project had fully

There are no items matching the current filter
There are no more items matching the current filter
Back to top